DSIP 5mg

Description

DSIP: A History and Overview

Delta Sleep-Inducing Peptide (DSIP) is a neuropeptide that was discovered in the 1970s during research aimed at isolating a substance capable of inducing sleep patterns in rabbits. DSIP is a nonapeptide, meaning it is composed of nine amino acids. Its unique structure and wide distribution throughout the body, including in the central nervous system, suggest a multifaceted role in human physiology. DSIP has garnered attention for its potential applications in treating sleep disorders, modulating endocrine regulation, and managing stress, among other health benefits.

DSIP Chemical Composition

• Chemical Structure: DSIP is a nonapeptide, meaning it consists of 9 amino acids, with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu.
• Synonyms: SLEEP INDUCING PEPTIDE;WAGGDASGE;TRP-ALA-GLY-GLY-ASN-ALA-SER-GLY-GLU;TRP-ALA-GLY-GLY-ASP-ALA-SER-GLY-GLU;TRP-ALA-GLY-GLY-ASP-ALA-SER-GLY-GLU 4H2O;DELTA SLEEP INDUCING PEPTIDE;DELTA SLEEP-INDUCING PEPTIDE 4H2O;DSIP
• CAS No: 62568-57-4
• Molecular Formula: The molecular formula for DSIP reflects its amino acid composition, which includes carbon (C), hydrogen (H), nitrogen (N), oxygen (O), and sulfur (S) atoms. The exact formula is C35H48N10O15.
• Stability: DSIP is relatively stable at room temperature but is best stored in lyophilized form at low temperatures (below -18°C) to maintain its potency over time. Once reconstituted with sterile water or saline, it should be used within a short period and stored in the refrigerator.
• Solubility: DSIP is soluble in water and saline, facilitating its administration through various routes, including intravenous (IV), intramuscular (IM), and subcutaneous (SC) injections.
• Mechanism of Action: The precise mechanism of action of DSIP remains under investigation. It is believed to modulate neurotransmitter systems and exert a regulatory effect on sleep, stress response, and endocrine regulation.
• Therapeutic Use: Research has explored DSIP’s potential in treating various conditions, including sleep disorders, chronic pain, and some forms of stress. However, its effectiveness and mechanism in these areas are still not fully understood.
• Efficacy: Studies on DSIP have shown mixed results. Some research suggests it may have beneficial effects on sleep patterns, particularly in enhancing delta wave sleep, while other studies have not found significant effects.
• Side Effects: There is limited information on the side effects of DSIP, partly due to the relatively small number of human studies. In available research, it has been generally well-tolerated.
• Safety Profile: The safety profile of DSIP in humans is not well-established, necessitating further research to understand its long-term effects and any potential adverse reactions.
• Legal Status and Availability: DSIP is not approved by the FDA or other regulatory agencies for medical use. It is available through various online sources as a research peptide, intended for scientific study and not for human consumption.
• Shelf Life: 36 months
• Appearance: White lipolyzed powder puck.

Mechanisms of Action

The precise mechanisms by which DSIP exerts its effects are not fully understood, but it is believed to influence neurotransmitter systems and modulate the activity of gamma-aminobutyric acid (GABA), the body’s primary inhibitory neurotransmitter. Studies suggest that DSIP may play a role in regulating sleep by modulating GABAergic mechanisms, thus promoting sleep induction and improving sleep quality. Additionally, DSIP has been shown to have an impact on the hypothalamic-pituitary-adrenal axis, potentially influencing the secretion of certain hormones such as cortisol, which plays a role in stress response and metabolic processes​​.

Therapeutic Applications

The primary interest in DSIP lies in its sleep-promoting properties. Sleep disorders, including insomnia and disturbed sleep patterns, affect a significant portion of the population. DSIP’s ability to induce delta wave sleep, the deepest and most restorative phase of sleep, without altering the natural sleep architecture, makes it a promising candidate for the treatment of sleep-related issues. Clinical trials and research studies have explored the use of DSIP in patients with insomnia and other sleep disorders, reporting improvements in sleep quality and duration​​.

Beyond its sleep-regulating effects, DSIP has been investigated for its potential in stress management and its role in endocrine regulation. The peptide may help mitigate stress by modulating the body’s stress response system, potentially offering benefits for individuals experiencing chronic stress or related conditions. Furthermore, its influence on endocrine functions suggests possible applications in treating hormonal imbalances and enhancing overall well-being​​.

Research and Clinical Studies

Research on DSIP has included both animal and human studies, aiming to elucidate its pharmacological profile and therapeutic potential. Studies in animals have demonstrated DSIP’s ability to enhance sleep patterns and modulate stress response mechanisms. In human clinical trials, DSIP has been evaluated for its efficacy in improving sleep quality, with some studies indicating positive outcomes in terms of increased sleep duration and improved sleep architecture​​.

Moreover, research has explored DSIP’s potential neuroprotective effects, suggesting that it may offer benefits in neurodegenerative conditions by protecting neuronal cells from damage and supporting cognitive functions. The peptide’s impact on hormonal regulation also opens avenues for investigating its role in conditions related to endocrine dysfunction, such as metabolic syndrome and certain types of diabetes​​.

Safety and Tolerability

The safety and tolerability of DSIP are crucial considerations for its therapeutic use. Clinical trials have generally reported that DSIP is well-tolerated by participants, with minimal side effects. However, further research is needed to fully understand its safety profile, especially with long-term use and in diverse patient populations​​.

Conclusion

Delta Sleep-Inducing Peptide presents a promising avenue for research and therapeutic applications, particularly in the realm of sleep disorders and stress management. Its potential benefits extend to endocrine regulation and neuroprotection, highlighting the peptide’s multifaceted role in human health. Ongoing research and clinical trials will be key in unlocking DSIP’s full therapeutic potential and understanding its mechanisms of action, safety, and efficacy in treating a range of conditions.

Referenced Citations

1. Delta-sleep-inducing peptide (DSIP): an update – An overview and update on DSIP’s discovery, characterization, and both sleep-related and extra-sleep effects.
   (https://pubmed.ncbi.nlm.nih.gov/3367267/)
2. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behavior in severe chronic insomnia – A study demonstrating DSIP’s efficacy in treating impaired sleep and daytime functions in middle-aged chronic insomniacs. (https://pubmed.ncbi.nlm.nih.gov/3758119/)
3. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes – Investigates DSIP’s potential action in humans suffering from chronic pain, considering its modulation interaction with endogenous opioid-peptidergic systems. (https://pubmed.ncbi.nlm.nih.gov/6548966/)
4. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients – A double-blind study exploring DSIP’s influence on sleep in chronic insomniac patients.
   (https://pubmed.ncbi.nlm.nih.gov/3583493/)
5. Delta sleep-inducing peptide (DSIP): a still unresolved riddle – Discusses the poorly documented hypothesis regarding DSIP as a sleep factor, highlighting the ongoing mystery surrounding its biological activity and natural occurrence. (https://pubmed.ncbi.nlm.nih.gov/16539679/)
6. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs – Evaluates DSIP’s effects on the sleep cycle of insomniac patients through polysomnographic recordings. (https://pubmed.ncbi.nlm.nih.gov/7028502/)
7. Delta sleep-inducing peptide alters bispectral index, the electroencephalogram, and heart rate variability when used as an adjunct to isoflurane anaesthesia – Investigates DSIP’s effects on heart rate, HRV, and the depth of anaesthesia during isoflurane anaesthesia.
   (https://pubmed.ncbi.nlm.nih.gov/11797457/)
8. Phosphorylated delta sleep inducing peptide restores spatial memory and p-CREB expression by improving sleep architecture at high altitude – Shows how improving sleep quality with p-DSIP restores spatial memory by upregulating CREB phosphorylation during simulated high altitude hypoxia. (https://pubmed.ncbi.nlm.nih.gov/21075155/)
9. Antiepileptic activity of delta sleep-inducing peptide and its analogue in metaphit-provoked seizures in rats – Explores DSIP and its analogue’s potential in reducing the severity of metaphit-induced audiogenic seizures in rats. (https://pubmed.ncbi.nlm.nih.gov/15938222/)
10. A clinical trial with DSIP – An open study treating severe insomnia with DSIP, showing normalization of sleep and improved mood and performance during the daytime.
    (https://pubmed.ncbi.nlm.nih.gov/6391925/)